Immunitas Therapeutics
MA - WalthamBiotechnology
Focus: Immunitas Therapeutics is a single cell genomics-based drug discovery company focused on oncology, founded in 2024 and currently at Series B stage. The company is early-stage and pre-revenue, leveraging advanced genomic technologies to identify novel immune targets.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Funding Stage
SERIES B
Open Jobs
0
About Immunitas Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow Immunitas Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
Growth
Acquired IL-15 receptor agonist in growth phase targeting infectious disease and immune activation; mechanism suggests potential for off-label immuno-oncology exploration.
Products & Portfolio (1)
Help build intelligence for Immunitas Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.